Poseida Therapeutics (PSTX) News Today → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free PSTX Stock Alerts $2.86 -0.11 (-3.70%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 25, 2024 | americanbankingnews.comPoseida Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.43) Per Share, HC Wainwright Forecasts (NASDAQ:PSTX)May 24, 2024 | marketbeat.comQ2 2024 Earnings Estimate for Poseida Therapeutics, Inc. (NASDAQ:PSTX) Issued By HC WainwrightPoseida Therapeutics, Inc. (NASDAQ:PSTX - Free Report) - Equities research analysts at HC Wainwright boosted their Q2 2024 earnings per share estimates for Poseida Therapeutics in a research report issued to clients and investors on Wednesday, May 22nd. HC Wainwright analyst A. He now expects thaMay 24, 2024 | americanbankingnews.comPoseida Therapeutics, Inc. Forecasted to Earn Q3 2025 Earnings of ($0.49) Per Share (NASDAQ:PSTX)May 23, 2024 | marketbeat.comPoseida Therapeutics, Inc. to Post Q3 2025 Earnings of ($0.49) Per Share, HC Wainwright Forecasts (NASDAQ:PSTX)Poseida Therapeutics, Inc. (NASDAQ:PSTX - Free Report) - HC Wainwright issued their Q3 2025 earnings per share estimates for Poseida Therapeutics in a note issued to investors on Wednesday, May 22nd. HC Wainwright analyst A. He expects that the company will earn ($0.49) per share for the quarter.May 23, 2024 | americanbankingnews.comPoseida Therapeutics' (PSTX) "Buy" Rating Reaffirmed at HC WainwrightMay 22, 2024 | marketbeat.comPoseida Therapeutics' (PSTX) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of Poseida Therapeutics in a report on Wednesday.May 17, 2024 | marketbeat.comPoseida Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.38) Per Share, William Blair Forecasts (NASDAQ:PSTX)Poseida Therapeutics, Inc. (NASDAQ:PSTX - Free Report) - Research analysts at William Blair lowered their Q2 2024 earnings estimates for shares of Poseida Therapeutics in a report released on Wednesday, May 15th. William Blair analyst S. Corwin now forecasts that the company will post earnings peMay 15, 2024 | finanznachrichten.dePoseida Therapeutics, Inc.: Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024May 14, 2024 | investorplace.comPSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q1 2024May 14, 2024 | prnewswire.comPoseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024May 9, 2024 | prnewswire.comPoseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual MeetingMay 3, 2024 | finance.yahoo.comBroker Revenue Forecasts For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Are Surging HigherMay 2, 2024 | marketbeat.comPoseida Therapeutics' (PSTX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Poseida Therapeutics in a research note on Thursday.May 2, 2024 | markets.businessinsider.comStrategic Advancements and Favorable Deal Terms Reinforce Buy Rating for Poseida TherapeuticsMay 2, 2024 | markets.businessinsider.comStrong Buy Rating for Poseida Therapeutics Amidst Strategic Partnerships and Robust CAR-T Manufacturing CapabilitiesMay 1, 2024 | markets.businessinsider.comStrategic Partnership Boosts Poseida Therapeutics’ Solid Tumor Treatment Capabilities and Underpins Buy RatingMay 1, 2024 | markets.businessinsider.comAstellas, Poseida Collaborate To Develop Novel Allogeneic Cell Therapies In OncologyMay 1, 2024 | prnewswire.comAstellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyMay 1, 2024 | marketwatch.comPoseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos BiosciencesMay 1, 2024 | msn.comBiotech Soars on Research Collaboration And License Agreement ReleaseMay 1, 2024 | msn.comPoseida gains on cell therapy pact with AstellasMay 1, 2024 | finance.yahoo.comAstellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyApril 22, 2024 | marketbeat.comPoseida Therapeutics (NASDAQ:PSTX) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of Poseida Therapeutics in a research note on Monday.April 18, 2024 | prnewswire.comPoseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual MeetingApril 17, 2024 | finance.yahoo.comPoseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline FocusApril 17, 2024 | prnewswire.comPoseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline FocusApril 16, 2024 | msn.comPalisade Bio, Marinus Pharmaceuticals, Poseida Therapeutics among healthcare moversApril 9, 2024 | investing.comPoseida reports promising results for myeloma therapyApril 8, 2024 | prnewswire.comPoseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple MyelomaApril 1, 2024 | prnewswire.comPoseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 26, 2024 | finanznachrichten.dePoseida Therapeutics, Inc.: Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical OfficerMarch 26, 2024 | msn.comPoseida Therapeutics appoints Syed Rizvi as Chief Medical OfficerMarch 25, 2024 | finance.yahoo.comPoseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical OfficerMarch 19, 2024 | finance.yahoo.comPoseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceMarch 15, 2024 | finance.yahoo.comPSTX Apr 2024 5.000 putMarch 15, 2024 | finanznachrichten.dePoseida Therapeutics, Inc.: Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple MyelomaMarch 13, 2024 | finance.yahoo.comPoseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple MyelomaMarch 13, 2024 | msn.comPoseida spikes after FDA orphan status for CAR-T therapyMarch 11, 2024 | msn.comEQT, Genie Energy And Other Big Stocks Moving Lower On MondayMarch 10, 2024 | finance.yahoo.comUS$14.00 - That's What Analysts Think Poseida Therapeutics, Inc. (NASDAQ:PSTX) Is Worth After These ResultsMarch 9, 2024 | finance.yahoo.comPoseida Therapeutics Full Year 2023 Earnings: Beats ExpectationsMarch 8, 2024 | markets.businessinsider.comBuy Rating for Poseida Therapeutics Amid Strong Financials and Promising Clinical UpdatesMarch 8, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Poseida Therapeutics (PSTX), Lumos Pharma (LUMO)March 8, 2024 | finance.yahoo.comPoseida Therapeutics Inc (PSTX) Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 8, 2024 | investorplace.comPSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q4 2023March 7, 2024 | finance.yahoo.comPoseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023March 6, 2024 | finanznachrichten.dePoseida Therapeutics, Inc.: Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 1, 2024 | morningstar.comPoseida Therapeutics Inc Ordinary SharesFebruary 27, 2024 | finance.yahoo.comInstitutional investors own a significant stake of 41% in Poseida Therapeutics, Inc. (NASDAQ:PSTX)February 27, 2024 | marketbeat.comAcadian Asset Management LLC Decreases Stock Holdings in Poseida Therapeutics, Inc. (NASDAQ:PSTX)Acadian Asset Management LLC trimmed its holdings in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX - Free Report) by 23.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 851,839 Get Poseida Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. PSTX Media Mentions By Week PSTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PSTX News Sentiment▼1.080.85▲Average Medical News Sentiment PSTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PSTX Articles This Week▼162▲PSTX Articles Average Week Get Poseida Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BDTX News Today CRBU News Today SOPH News Today ADAP News Today MGX News Today IVVD News Today TNYA News Today CHRS News Today ZURA News Today IPHA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PSTX) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeYou won't believe what Citigroup just did to it's depositorsAmerican AlternativeWARNING about the death of the U.S. dollar…Colonial MetalsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poseida Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
